Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 91,088 shares at $0.94 ($88K) on 2025-12-01, disclosed to the SEC on 2025-12-01.
Scheduled sale ($88k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.98 | 38,978 | $38K | 43.5% |
| 2 | $0.99 | 13,014 | $13K | 14.7% |
| 3 | $0.94 | 39,096 | $37K | 41.8% |
| Total | $0.96 avg | 91,088 | $88K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |